HZT-501

DRUG3 trials

Sponsors

Amgen

Conditions

Chronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue PainOsteoarthritisPeptic UlcerRheumatoid Arthritis

Phase 3

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

CompletedNCT00450658

AmgenPeptic Ulcer

Start: 2007-03-31End: 2008-10-31Updated: 2024-12-16

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

CompletedNCT00613106

AmgenChronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain +2

Start: 2007-09-30End: 2008-10-31Updated: 2024-12-17

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

CompletedNCT00984815

AmgenChronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain +2

Start: 2009-09-30End: 2011-07-31Updated: 2024-12-18

Related Papers

Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons

The Physician and Sportsmedicine2015-07-038 citations

One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.

2015-01-093 citations